SQLite Web: event_store.db

Update row sig_4fe6f38bc920 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","company":"WORK Medical Technology Group LTD","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","article_chars":3208,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_e43755eab130cbcb","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:17:00.903870+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt","source_event_id":"evt_d1d095b6bf0f","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"36042bd989851c48","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-15","2026-04-16","2026-03-23","2025-01","2024-07","2019-10","2021-01","2021-06","2021-07","2024-06"],"entities":[{"asset_class":"equity","name":"WORK Medical Technology Group LTD","relevance":"high","symbol":"WOK","type":"issuer"},{"asset_class":"person","name":"Xiaoyang Li","relevance":"high","symbol":"","type":"person"},{"asset_class":"person","name":"Qisheng Lin","relevance":"high","symbol":"","type":"person"},{"asset_class":"governance","name":"Audit Committee","relevance":"medium","symbol":"","type":"committee"},{"asset_class":"governance","name":"Compensation Committee","relevance":"medium","symbol":"","type":"committee"},{"asset_class":"governance","name":"Nominating and Corporate Governance Committee","relevance":"medium","symbol":"","type":"committee"},{"asset_class":"regulation","name":"Nasdaq Listing Rule 5605(a)(2)","relevance":"low","symbol":"","type":"rule_reference"}],"event_type":"other","information_gaps":["What changed vs prior known state is not provided in the signal; only the current 6-K content is available here.","No financial guidance or financial implications are disclosed in the provided text.","No details are provided about whether Dr. Lin replaces Li specifically in each committee role beyond the stated appointments; prior committee composition is not included.","No additional context is provided regarding the company\u2019s governance rationale beyond the stated personal reasons for resignation and independence determination."],"key_facts":["The company filed a Form 6-K for the month of April 2026.","On March 23, 2026, Mr. Xiaoyang Li resigned as an independent director and from the Board and as a member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, and as chairperson of the Compensation Committee, effective March 23, 2026.","Mr. Li\u2019s resignation was due to personal reasons.","On March 23, 2026, the company extended a director offer letter to Dr. Qisheng Lin, who accepted and signed a consent to act as a director.","On March 23, 2026, the Board ratified and approved Dr. Qisheng Lin\u2019s appointment as an independent director, effective March 23, 2026.","Dr. Qisheng Lin was appointed as a member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, and as chairperson of the Compensation Committee.","The filing states Dr. Lin has extensive experience in medicine and academic research, including roles at Renji Hospital (Shanghai Jiao Tong University School of Medicine) and prior work at Icahn School of Medicine at Mount Sinai.","The filing states Dr. Lin has no family relationship with any director or executive officer and has not been involved in any transaction with the company during the past two years requiring disclosure under Item 404(a) of Regulation S-K.","The Board determined Dr. Lin is an independent director as defined under Nasdaq Listing Rule 5605(a)(2).","The report is deemed incorporated by reference into the company\u2019s Form F-3 registration statement (File No. 333-289943) to the extent not superseded."],"numeric_claims":[],"primary_claim":"On March 23, 2026, independent director Xiaoyang Li resigned from the Board and related committees for personal reasons, and the Board appointed Dr. Qisheng Lin as an independent director and committee member/chairperson effective the same date.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"WORK Medical Technology Group LTD (WOK) filed a Form 6-K reporting the resignation of independent director Xiaoyang Li and the appointment of independent director Qisheng Lin, effective March 23, 2026.","topics":["SEC filing","Form 6-K","board of directors","independent director resignation","independent director appointment","audit committee","compensation committee","nominating and corporate governance committee"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 WORK Medical Technology Group LTD \u00b7 Filed 20260415","ticker":"WOK","tickers":["WOK"],"title":"WOK filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/1929783/0001213900-26-044086.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel